Romidepsin Therapy Over 5 Years in a Clinical Setting-Real-world Experience

JAMA Oncol. 2016 Jun 1;2(6):794-5. doi: 10.1001/jamaoncol.2016.0072.

Authors

Susan E Bates¹, Larisa J Geskin²

Affiliations

¹ Division of Hematology/Oncology, Columbia University Medical Center, New York, New York.
² Division of Cutaneous Oncology, Department of Dermatology, Columbia University Medical Center, New York, New York.

PMID: 27054784
DOI: 10.1001/jamaoncol.2016.0072

No abstract available

MeSH terms

Adult
Aged
Depsipeptides / adverse effects
Depsipeptides / therapeutic use*
Dose-Response Relationship, Drug
Drug-Related Side Effects and Adverse Reactions / classification
Drug-Related Side Effects and Adverse Reactions / pathology
Female
Histone Deacetylase Inhibitors / adverse effects
Histone Deacetylase Inhibitors / therapeutic use*
Humans
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / pathology
Male
Medical Records
Middle Aged
Retrospective Studies
Treatment Outcome

Substances

Depsipeptides
Histone Deacetylase Inhibitors
romidepsin